Goldman Sachs 47th Annual Global Healthcare Conference 2026
Logotype for Merit Medical Systems Inc

Merit Medical Systems (MMSI) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Merit Medical Systems Inc

Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

8 Jun, 2026

Strategic and operational changes

  • Recent re-segmentation aligns internal and external reporting, improving accountability and clarity across platforms.

  • CEO transition to Martha brought a focus on foundational and therapeutic segments, streamlining decision-making and reporting.

  • Platforms are not full business units but have increased autonomy and shared resources, with marketing and R&D closely integrated.

  • Product life cycle management and portfolio rationalization are ongoing, with recent divestitures and SKU consolidation.

  • International markets, especially Europe and China, are performing in line with expectations, with China shifting from a headwind to a modest contributor.

Growth drivers and portfolio outlook

  • Growth is primarily volume-driven, with pricing and new product launches providing additional support.

  • Foundational segment has a three-year CAGR of 6%, while therapeutic is at 11%; OEM expected to stabilize at mid to high single-digit growth.

  • Recent acquisitions in endoscopy and oncology (including View Point) are expected to drive further growth.

  • The View Point acquisition expands the addressable market, with revenue ramping from $2M to $15M over two years.

  • M&A activity remains focused on deepening existing areas rather than expanding into new ones, with no pressure to acquire for growth padding.

Financial performance and guidance

  • Q1 foundational business grew 5.5% organically, therapeutic grew 12%, both in line with multi-year CAGRs after adjusting for divestitures and recalls.

  • OEM business is rebounding, with orders returning and expected mid-single-digit growth in Q2.

  • Tariffs and other headwinds are being managed, with some reimbursement received and ongoing adjustments expected after Q2.

  • Operating margin expansion is expected to continue, though at a slower pace than the previous five years.

  • Guidance remains realistic and achievable, with a focus on delivering on long-range plans rather than overpromising.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more